Meloxicam/Rizatriptan Combo Under Review for Migraine Treatment
The application is supported by data from the phase 3 MOMENTUM and INTERCEPT trials.
The application is supported by data from the phase 3 MOMENTUM and INTERCEPT trials.
The approval is supported by data from the phase 3 STOP 301 study, which evaluated the safety and tolerability of Trudhesa in 354 adults with migraine.
Nerivio is a wireless remote electrical neuromodulation device approved for the acute treatment of episodic or chronic migraine in patients 12 years of age and older.
Researchers searched publication databases for studies of the gut-brain connection, migraine, and gastric disorders.
Rimegepant is an oral calcitonin gene-related peptide receptor antagonist.
Atorvastatin may have augmentative effects with sodium valproate in the reduction of migraines with aura.
Researchers presented their study results comparing headache education with mindfulness-based stress reduction for patients with migraine at the AAN 2021 Virtual Annual Meeting,
Paul G. Mathew, MD and Steven D. Bender, DDS, uniquely encounter patients with TMD and migraine in their respective practice and offer their insight regarding the diagnosis and management this often overlooked comorbidity.
Distinct pattern of abnormal brain connection on fMRI can assist in the differentiation between a healthy brain and a brain with migraine without aura.
Ubrogepant, the newly approved calcitonin gene-related peptide antagonist, can relieve migraine symptoms within 2 hours after initial dose.